Full-Time

Senior Principal Validation Engineer

Posted on 10/31/2025

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

No salary listed

Albuquerque, NM, USA

In Person

Category
QA & Testing (1)
Requirements
  • Bachelor’s degree in Science, Engineering, or relevant field with a minimum of fifteen (15) years validation experience in pharmaceutical validation or aseptic/sterile product facility
  • Master’s degree in Science, Engineering, or relevant field with thirteen (13) years validation experience in pharmaceutical validation or aseptic/sterile product facility
  • Experience with validation tools and processes, including temperature mapping and use of Kaye Validator
  • Experience with FDA and EU regulations for pharmaceuticals and validation requirements
Responsibilities
  • Develop and execute required protocols and complete reports for equipment, process utility, test, and revalidations as assigned
  • Develop and write Standard Operating Procedures for new processes and equipment
  • Support department projects by assisting engineers, calibrations, and validations on ongoing projects
  • Support internal and external audits by providing and/or presenting data appropriate to the investigation as required
  • Keep Department Management and personnel aware of Validation related issues that may have a regulatory compliance or financial impact
  • Responsible for providing leadership to the contractors supporting the Validation program
  • Ensure change controls, records, and procedures follow current Good Manufacturing Practices (cGMP) as well as Good Documentation Practices (GDPs)
  • Review and write validation protocols, final reports, and summaries of work for release of equipment tested
  • Serve as validation liaison between the site and customers or regulatory agencies during facility audits
  • Provide leadership and guidance to validation staff and contractors in the performance of their duties
  • Develop and support departmental strategic goals to assure the highest quality standards and regulatory compliance
  • Review and approve qualification, validation, re-qualification, and re-validation documents for equipment and manufacturing process protocols and final report
  • Review and approve validation protocols for computer related systems (as needed), environmental monitoring (if applicable), process validations and cleaning validations
  • Coordinate and prioritize validation activities for the facility, in particular for key projects, according project timelines to ensure timeliness and with minimal disruption of production schedules, as applicable
  • Write, update, approved, and maintain pertinent Validation Master Plans for the facility
  • Ensure goals and objectives are met by contractors supporting Validation of existing projects
  • Participate in the review of changes made under the Change Control System from a validation perspective
  • Provide validation oversight to facility, utility and equipment upgrades
  • Provide validation input to technology transfers
  • Author, review, or approve impact assessments prepared by the Validation Department for change controls
  • Read/interpret SOPs to ensure compliance
  • Maintain up to date trainings
  • Other duties as assigned

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$1.1B

Headquarters

Albany, New York

Founded

1991

Simplify Jobs

Simplify's Take

What believers are saying

  • Biologics segment expansion under Steve Lavezoli accelerates high-margin pharmaceutical outsourcing revenue growth.
  • Carterra partnership positions Curia to capture Pacific Northwest biotech demand in antibody discovery services.
  • Gerald Auer's CFO appointment signals M&A activity and potential strategic initiatives enhancing shareholder value.

What critics are saying

  • Pace Life Sciences acquisition of New Jersey lab erodes Curia's analytical testing capacity and revenue.
  • Larger CDMOs like Lonza and Catalent undercut Curia on biologics capacity, stealing biotech contracts.
  • FDA scrutiny on srRNA manufacturing defects from Replicate Bioscience Phase 1 triggers potential client exodus.

What makes Curia unique

  • Pioneer in self-replicating RNA manufacturing, demonstrated through Replicate Bioscience Phase 1 clinical trial support.
  • Integrated enzymatic doggybone DNA technology via Touchlight collaboration expands mRNA manufacturing competitive advantages.
  • End-to-end CDMO services from discovery through cGMP manufacturing differentiate Curia from specialized competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.

INACTIVE